Venus Medtech – First in Vivo Application
Instituo De Cardiologia hospital completed Venibri’s in vivo application in Argentina, a breakthrough for transcatheter heart valve (THV). Venibri is the current leading pre-packaged transcatheter heart valve system that utilizes innovative dry tissue technology. The first clinical application in Argentina was marked as a milestone in THV domain. According to Mr. Zi, the CEO and founder of Venus Medtech, Venus Medtech is going to launch multiple global clinical trails in China, Brazil, India and Europeans countries.
According to Venus Medtech General Manager Zi Zhenjun, more than 200,000 TAVI procedures have been performed worldwide since the team led by Professor Alain Cribier conducted the world's first TAVI procedure in 2002 in Rouen, France. Martin Leon, Professor of Medicine at Columbia University Medical Center, said during TCT 2015 that the TAVR market is expected to surpass the coronary artery intervention market worldwide by 2025. More than 400 TAVR procedures have been performed in China since Dr. Ge Junbo from Zhongshan Hospital of Fudan University, completed China's first TAVR procedure in 2010. Venus Medtech's Venus A-Valve, with independent intellectual property rights, is the world's only transcatheter aortic valve solution meeting China Food and Drug Administration clinical requirement.
Qiming Venture Partners managing partner Nisa Leung commented, "Venus Medtech is a leading developer of innovative cardiac valve products in China. We are confident about its industry advantages in technology and resources, and are convinced that under the leadership of its seasoned management team, Venus Medtech will become a leader in the R&D of cardiac intervention therapies in China and even around the world."
HISKY MED – Series B Financing
HISKY MED closed a $15 million series B financing round from Legend Capital, 3E Bioventures and Chang’an Capital with Haoyue Capital as the exclusive financial advisor.
HISKY MED is a rapidly growing company specialized in developing, manufacturing and marketing of high-tech medical equipment for non-invasive liver diagnosis. Its self-developed non-invasive liver fibrosis diagnostic system, FibroTouch, is capable of making quantitative detection and assessment of liver fibrosis and hepatic steatosis with low frequency shear wave technology. -- ITJuzi
Partnred with Tsinghua University, HISKY MED owns over 40 patents and published 70 paper. FibroTouch received experts acknowledge at The 2016 Asian Pacific Association for the Study of the Liver.
Legend Capital is a leading early-stage venture capital and expansion-stage growth capital managing several USD and RMB funs with a total $4.3 billion. Legend Capital accomplished 40 exits through M&A.
Yuemei.com – Series B Financing
Yuemei.com closed a $15 million series B financing round led by SAIF Partners and Ce Yuan Ventures, and Haoyue Capital was the exclusive financing advisor. This round of financing empowers Yuemei.com’s strategic expanding of offline stores in cities.
Founded in 2014, Yuemei.com is an O2O platform of cosmetic surgery procedures. Yuemei provides services including beauty consultation, online appointments and purchases for customers.
Yuemei has over 1,100 registered practitioners in its marketplace, scattered across mainland China. The site aims to be the starting point for patients, male or female, seeking plastic surgeons, with local listings, prices, and a profile page for each doctor that resembles a personal social media homepage. From there, users can begin a consultation.
SAIF Partners is a leading private equity firm that provides primarily growth capital to highly performing companies and business in China. SAIF Partner is managing over $4 billion with a focus on TMT, Healthcare, Cleantech.
Ce Yuan Ventures is an early stage venture capital firm focused on IT and emerging companies. Successful portfolios include UC, Jiayuan.com, Dianping.com, XunLei etc.
MALO CLINIC – Series B Financing
MALO CLINIC closed a $12 million series B financing round with GGV Capital as the lead investor, and other investors include HighLight Capital, Shanghai Li Ying Investment Management Center etc. Haoyue Capital was the exclusive financial consultant.
Since its establishment in 1995, MALO CLINIC sustained its exponential growth in several distinguished factors that were crucial for in just a few years becoming an international brand with global recognition in Implantology and Dental Aesthetics.
Back to 2013, MALO CLINIC entered China and opened the flagship clinic at CBD, Beijing. A quote from Mr. Shao, the chairman of MALO CLINIC China, “We hope to cooperate with more excellent professional dentist and managerial talents and partners who are engaged in high-quality dental services and have the same philosophy of professional care and ingenious spirit as MALO CLINIC so as to jointly make contribution to the development of China domestic private stomatological industry,”
GGV Capital is managing eight funds with $3.8 billion in total, and operates in China and U.S. GGV Capital has achieved remarkable 28 IPOs exit since the establishment 16 years ago. Airbnb, Alibaba and Didi Chuxing were once backed by GGV Capital.
HighLight Capital is a venture capital and a private equity investment firm that specializes in angel, early stage, middle stage, growth capital, IPO and in PIPE investments. It typically invests in the healthcare sector. Current portfolios are Brain Doctor Group(BDG), KingYee etc.
Haoyue Capital at The Health Industry Summit (iHIS)
Mr. Liu and Hong, the founder of CN-Healthcare, served as moderators at iHIS 2016.
The Health Industry Summit (tHIS) - EXPO and Congress is the new umbrella global Pharmaceutical and Medical industry event in Asia, a fastest growing health market.
The exhibition widely covers ten thousands of products such as medical imaging, in vitro diagnosis, electronics, optics, first aid, rehabilitation nursing, medical information technology and outsourcing services, and it provides services to the entire medical industry chain from the source to the end of the medical equipment industry in a direct and all-round way. bulk pharmaceuticals, fine chemicals & intermediates, excipients & drug formulation, pharmaceutical packaging material & machinery. OTC Drugs & Prescription Drugs of Chemical, Patented TCM and Biopharmaceuticals, Pharmaceutical Technology & Research, Pharmaceutical R&D Contract Outsourcing, Facilities and Services for pharmacies.
Venus Medtech – Series D Financing
Venus Medtech chose Goldman Sachs as its round D investor and raised $37 million. The capital will boost the R&D and promotional activities of transcatheter heart valve (THV) products. Haoyue capital was the exclusive financial consultant.
Venus Medtech already has a transcatheter aortic valve replacement (TAVR), the A-Valve, on the market in the People’s Republic and said a pulmonary valve is in clinical trials. The A-Valve is the only TAVR device that meets China Food & Drug Administration requirements. The Venus P-valve pulmonary replacement has already been implanted in more than 40 patients, and the current goal is to win CE Mark approval. They will reportedly be enrolling patients to accomplish this in the early half of the year.
Symap Medical – Series B Financing
Xinmai Medical Devices raised $10 million from series B financing round. Sequoia Capital led this round and followed by Softbank China Capital (SBCVC). Haoyue Capital was the exclusive financial advisor in the transaction.
Symap Medical is developing a device for mapping and ablating renal nerves distributed on the renal artery. This innovation increases physicians’ accuracy in performing renal denervation procedure, a novel therapy approved for uncontrolled hypertension.
Distinct HealthCare – Series B Financing
Haoyue Capital helped Distinct HealthCare close series B financing with a Hong Kong-based capital and Martix Partners (series A investor), and raise $17.5 million.
Founded in 2012, Distinct HealthCare operates healthcare clinics and medical centers. It offers medical services in the areas of pediatrics, internal medicine, gynecology, and family medicine, which include common colds, headaches, sinusitis, allergies, acute bronchitis, diabetes, hypertension, upset stomach, bladder infection, chronic kidney disease, etc. The company also services in the areas of emergency support and referral to specialists, such as arranging hospital admittance and referring patients to specialists in Shenzhen, Hong Kong, Guangzhou, and Beijing.
Matrix Partner China affiliated Matrix Partners U.S. in 2008. The team invests sectors including TMT, healthcare and SaaS in China. Past portfolio includes Baidu, iKang, Kanghui Medical etc.
Quyiyuan.com – Series A Financing
Highlight Capital and Softbank China Capital (SBCVC) was committed to provide a proximate $10 million series A round for Quyiyuan.com. Highlight Capital is a leading RMB healthcare investment fund. Shanghai Quyiyuan Network Technology Co., Ltd. operates a mobile internet medical consultation and service platform.
HighLight Capital is a venture capital and a private equity investment firm that specializes in angel, early stage, middle stage, growth capital, IPO and in PIPE investment. It typically invests in the healthcare sector. Current portfolios are Brain Doctor Group(BDG), KingYee etc.
By far, Haoyue core team has closed 4 deals in mHealth market in the past 7 years.
MALO CLINIC – Series A Financing
MALO CLINIC received proximate $10 million from Highlight Capital. Haoyue Capital was the exclusive financial consultant in the transaction.
Haoyue core team has completed numbers of capital-raising, M&A and IPO deals for leading independent labs and specialty hospitals including women & children, cosmetic surgery, cardiovascular and geriatric. MALO CLINIC was our hospital client that specialized in dental.
HealForce – Series A Financing
Haoyue Capital acted as exclusive financial advisor for HealForce in 2013. This was the largest deal in medical device market.
Established in 1989, Heal Force Bio-MediTech Holdings Limited is a Chinese manufacturer of medical equipment, laboratory equipment, and healthcare equipment. With over two decades of experience in the field, Heal Force are able to provide a vast range of products, including our electrosurgical generator, anesthetic machine, patient monitor, biological safety cabinet, laboratory centrifuge, pulse oximeter, massager, and more.
KingYee – Series B Financing
Haoyue acted as the exclusive financial advisor for KingYee in 2014. Investors including Highlight Capital and Softbank China Venture Capital (SBCVC), were committed to a $15 million B round capital raising.
KingYee develops mobile-based communication equipment for healthcare industry and possesses the largest mHealth market share in China. KingYee’s product line includes network, equipment and applications. Served as the dominant vendor, KingYee Wireless Nurse have been implemented in over 150 hospitals.
KingYee is a leading Hospital Resource Planning System (HRP) vendor. Started from 2007, KingYee has been the explorer and pioneer in this field. The successful implementation of HRP increases the operational efficiency and provides comprehensive data for managerial planning and strategy.